Merck KGaA Stock
€162.90
Your prediction
Merck KGaA Stock
Pros and Cons of Merck KGaA in the next few years
Pros
Cons
Performance of Merck KGaA vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Merck KGaA | 1.840% | 1.847% | 1.427% | -7.757% | 11.115% | 9.555% | 60.689% |
Bayer AG | -0.370% | 8.048% | -2.110% | -49.181% | -15.215% | -46.693% | -49.780% |
Pfizer Inc. | 0.580% | 1.181% | 3.421% | -31.025% | -1.533% | -16.191% | -27.515% |
Elanco Animal Health Inc. | 1.230% | 0.946% | -1.581% | 77.350% | 10.503% | -36.722% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.It appears that Merck, operating under the US symbol MKGAF, showcases stable financial performance within the pharmaceuticals industry. The company has shown consistent growth in total assets and net income in recent years, and its overall financial position and liquidity seem to be in good shape.
In conclusion, Merck's financials reveal a generally positive situation for the company, with growth in total assets, net income, and operating cash flows. However, certain areas, such as increased long-term debt, negative net tangible assets, and changes in net working capital necessitate careful monitoring. As an analyst, monitoring Merck's financial performance and management strategies will be crucial to ensure sustained growth and stability in the coming years.
Comments
News
2 Monster Stocks to Buy Without Any Hesitation
Investing in stocks is a great way for most people to grow their wealth over time. However, all stocks aren't created equal. Some are unlikely to deliver anything resembling solid returns over the
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
January was a big month for pharmaceutical stocks, with Merck (NYSE: MRK), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market
3 companies that more than doubled analyst EPS estimates
Earnings season is well underway, and the winner-and-loser separation continues to grow. Of the companies that beat consensus analyst estimates, even fewer go well beyond and exceed analyst